CLOV Stock Recent News

WILMINGTON, Del., April 08, 2025 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (Nasdaq: CLOV) (“Clover,” “Clover Health” or the “Company”), today announced that it will report first quarter 2025 financial results after market close on Tuesday, May 6, 2025. Management will host a conference call and webcast at 5:00 p.m. Eastern Time on May 6, 2025, to discuss Clover Health's first quarter 2025 business and financial results.

Dr. Shelly Gupta Brings Over a Decade of Medicare Advantage and Healthcare Leadership Experience Dr. Shelly Gupta Brings Over a Decade of Medicare Advantage and Healthcare Leadership Experience

Clover Health Investments' AI capabilities are a major driver for its topline and bottom-line improvements in FY 2024. Clover Health's MCR in Q4 represented a decline from Q3, unlike past years, and rivaled its Q2 MCR, a sign of the impact of its AI capabilities. While Clover expects its margins to contract in FY 2025, its increased investments this year set it up for a highly profitable future starting from FY 2026, in my opinion.

Shares of Hims & Hers Health Inc. NYSE: HIMS have made a splash in recent weeks, reaching a new all-time high of just under $73 per share. However, a few days later, most of the upside moved right back, crashing down to as low as $36 per share.

New functionality within Counterpart Assistant uses Google Cloud's Vertex AI Search to give clinicians comprehensive insights across multiple sources of patient health data New functionality within Counterpart Assistant uses Google Cloud's Vertex AI Search to give clinicians comprehensive insights across multiple sources of patient health data

Clover Health's fourth-quarter 2024 results continue to benefit from the strength of its strong member retention. Strong revenue outlook bodes well.

Clover Health Investments, Corp. (NASDAQ:CLOV ) Q4 2024 Earnings Conference Call February 27, 2025 5:00 PM ET Company Participants Ryan Schmidt - Investor Relations Andrew Toy - Chief Executive Officer Peter Kuipers - Chief Financial Officer Conference Call Participants Jonathan Yong - UBS Tolf Cormanon - Craig Hallam Operator Ladies and gentlemen, good afternoon and welcome to the Clover Health Fourth Quarter and Full Year 2024 Earnings Conference Call. At this time, all participants are in a listen-only mode.

Clover Health Investments, Corp. (CLOV) came out with quarterly earnings of $0.02 per share, beating the Zacks Consensus Estimate of a loss of $0.07 per share. This compares to loss of $0.12 per share a year ago.

Full year 2024 GAAP Net loss from continuing operations improves by $164 million year-over-year Full year 2024 Adjusted EBITDA of $70 million, representing an increase of $112 million year-over-year Company well positioned to invest in membership growth and Clover Assistant technology, while maintaining strong profitability Issues full year 2025 guidance: Average Medicare Advantage membership of 103,000 - 107,000, representing 30% growth year-over-year at the midpoint Insurance revenue between $1.800 billion and $1.875 billion, representing 37% growth year-over-year at the midpoint Adjusted EBITDA profitability between $45 million and $70 million Adjusted Net income between $45 million and $70 million WILMINGTON, Del., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (Nasdaq: CLOV) (“Clover,” “Clover Health” or the “Company”), today reported financial results for the fourth quarter and full year 2024.

WILMINGTON, Del., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (Nasdaq: CLOV) (“Clover Health”), today announced its participation in the following investor conferences: CFO, Peter Kuipers, will participate in the 2025 Jefferies Value-Based Healthcare Summit on Monday, March 10, 2025.